Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey

Simple item page
dc.contributor.authorBakırtaş M.
dc.contributor.authorDal M.S.
dc.contributor.authorYiğenoğlu T.N.
dc.contributor.authorGiden A.O.
dc.contributor.authorSerin I.
dc.contributor.authorBaşcı S.
dc.contributor.authorKalpakci Y.
dc.contributor.authorKorkmaz S.
dc.contributor.authorEkinci O.
dc.contributor.authorAlbayrak M.
dc.contributor.authorBasturk A.
dc.contributor.authorOzatli D.
dc.contributor.authorDogu M.H.
dc.contributor.authorHacıbekiroglu T.
dc.contributor.authorÇakar M.K.
dc.contributor.authorUlas T.
dc.contributor.authorMiskioglu M.
dc.contributor.authorGulturk E.
dc.contributor.authorEser B.
dc.contributor.authorAltuntas F.
dc.date.accessioned2024-07-22T08:03:30Z
dc.date.available2024-07-22T08:03:30Z
dc.date.issued2023
dc.description.abstractA multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least ≥ two lines of therapy. Patients’ treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 ± 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients. © 2023 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia (Italian Society of Chemotherapy).
dc.identifier.DOI-ID10.1080/1120009X.2023.2208439
dc.identifier.issn1120009X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12314
dc.language.isoEnglish
dc.publisherTaylor and Francis Ltd.
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectDexamethasone
dc.subjectHumans
dc.subjectLenalidomide
dc.subjectMiddle Aged
dc.subjectMultiple Myeloma
dc.subjectRetrospective Studies
dc.subjectTurkey
dc.subjectbeta 2 microglobulin
dc.subjectdexamethasone
dc.subjecthemoglobin
dc.subjectixazomib
dc.subjectlactate dehydrogenase
dc.subjectlenalidomide
dc.subjectproteasome inhibitor
dc.subjectantineoplastic agent
dc.subjectdexamethasone
dc.subjectixazomib
dc.subjectlenalidomide
dc.subjectabsolute neutrophil count
dc.subjectadult
dc.subjectadverse event
dc.subjectaged
dc.subjectanemia
dc.subjectArticle
dc.subjectatrial fibrillation
dc.subjectbleeding
dc.subjectclinical practice
dc.subjectconstipation
dc.subjectcreatinine clearance
dc.subjectdemographics
dc.subjectdiarrhea
dc.subjectdisease exacerbation
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectECOG Performance Status
dc.subjectfemale
dc.subjectfollow up
dc.subjectglomerulus filtration rate
dc.subjecthuman
dc.subjecthypertension
dc.subjectInternational Staging System
dc.subjectlaboratory test
dc.subjectline of treatment
dc.subjectliver toxicity
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmiddle aged
dc.subjectmulticenter study
dc.subjectmultiple cycle treatment
dc.subjectmultiple myeloma
dc.subjectneutropenia
dc.subjectobservational study
dc.subjectoverall response rate
dc.subjectplatelet count
dc.subjectprogression free survival
dc.subjectrash
dc.subjectretrospective study
dc.subjectsurvival
dc.subjectthrombocytopenia
dc.subjecttreatment response
dc.subjectTurkey (republic)
dc.subjectclinical trial
dc.subjectmultiple myeloma
dc.subjectturkey (bird)
dc.titleReal-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey
dc.typeArticle

Files

Collections

Scopus Koleksiyonu